<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zeng Y</submitter><funding>Medical Science and Technology Research Foundation of Guangdong Province</funding><funding>Startup Foundation for Doctor Talents of Ganzhou People&amp;apos;s Hospital</funding><funding>Startup Foundation for Doctor Talents of Ganzhou People's Hospital</funding><pagination>1052-1060</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12502934</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>46(11)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>To assess the diagnostic value of fluorine 18 ( 18 F)-labeled prostate-specific membrane antigen (PSMA)-1007 PET/MRI and compare with that of 18 F-PSMA-1007 PET/computed tomography (CT) for biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy.&lt;h4>Materials and methods&lt;/h4>We enrolled 40 patients who underwent 18 F-PSMA-1007 PET/CT and 18 F-PSMA-1007 PET/MRI for BCR after radical prostatectomy. Two readers independently assessed the images and determined their overall assessment of positive lesions on PET/MRI and PET/CT. The association between the patients' clinical characteristics and positive detection results on the PET/CT and PET/MRI was explored. The PET/CT and PET/MRI results were verified during a 24-month follow-up to calculate their d</pubmed_abstract><journal>Nuclear medicine communications</journal><pubmed_title>Diagnostic value of 18 F-prostate-specific membrane antigen-1007 PET/MRI versus 18 F-prostate-specific membrane antigen-1007 PET/computed tomography for biochemical recurrence of prostate cancer after radical prostatectomy.</pubmed_title><pmcid>PMC12502934</pmcid><funding_grant_id>2024040022</funding_grant_id><funding_grant_id>A2024144</funding_grant_id><pubmed_authors>Liao H</pubmed_authors><pubmed_authors>Jiang G</pubmed_authors><pubmed_authors>Zeng Y</pubmed_authors><pubmed_authors>Wu G</pubmed_authors><pubmed_authors>Zhong J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Diagnostic value of 18 F-prostate-specific membrane antigen-1007 PET/MRI versus 18 F-prostate-specific membrane antigen-1007 PET/computed tomography for biochemical recurrence of prostate cancer after radical prostatectomy.</name><description>&lt;h4>Objective&lt;/h4>To assess the diagnostic value of fluorine 18 ( 18 F)-labeled prostate-specific membrane antigen (PSMA)-1007 PET/MRI and compare with that of 18 F-PSMA-1007 PET/computed tomography (CT) for biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy.&lt;h4>Materials and methods&lt;/h4>We enrolled 40 patients who underwent 18 F-PSMA-1007 PET/CT and 18 F-PSMA-1007 PET/MRI for BCR after radical prostatectomy. Two readers independently assessed the images and determined their overall assessment of positive lesions on PET/MRI and PET/CT. The association between the patients' clinical characteristics and positive detection results on the PET/CT and PET/MRI was explored. The PET/CT and PET/MRI results were verified during a 24-month follow-up to calculate their d</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-04T06:22:25.028Z</modification><creation>2026-05-06T03:12:56.164Z</creation></dates><accession>S-EPMC12502934</accession><cross_references><pubmed>40660863</pubmed><doi>10.1097/MNM.0000000000002028</doi></cross_references></HashMap>